August 26, 2016 4:43 PM ET


Company Overview of Stemina Biomarker Discovery, Inc.

Company Overview

Stemina Biomarker Discovery, Inc., a metabolomics company, focuses on the discovery, development, and commercialization of molecular biomarkers to improve drug safety and human health. The company works on collaborative research projects and joint development agreements with strategic partners to develop drugs, identify targets, and discover molecular biomarkers for the diagnosis of diseases and customized treatment. It provides metabolomics and mass spectrometry services, as well as develops diagnostic biomarkers. The company’s cell-based assays arise from the strategic convergence of technologies, such as human embryonic stem (hES) cells and metabolomics. It uses mass spectrometry to analy...

504 South Rosa Road

Suite 150

Madison, WI 53719

United States

Founded in 2006





Key Executives for Stemina Biomarker Discovery, Inc.

Chief Executive Officer and Director
Director of BioAnalytical Chemistry
Senior Scientist of BioAnalytical Chemistry
Compensation as of Fiscal Year 2016.

Stemina Biomarker Discovery, Inc. Key Developments

Stemina Biomarker Discovery, Inc. Launches Ever Clinical Study of Metabolism of Children with Autism

Stemina Biomarker Discovery Inc. announced the launch of the clinical study of the metabolism of children with autism spectrum disorder ever conducted. The Children’s Autism Metabolome Project or “CAMP” study will enroll 1,500 subjects from six sites across the country. CAMP will attempt to confirm that sets of metabolic biomarkers can detect subtypes of ASD. This new study is an expanded version of Stemina’s three pilot studies of more than 500 children. CAMP is also designed to contribute to identification of new biomarkers with the goal of advancing a panel of tests for earlier diagnosis and more precise treatment of ASD based on the metabolism of patients. Metabolomics is the study of differences in a person's metabolism as genomics is the study of differences in a person's genes. Metabolomics focuses on identifying normal and abnormal patterns of small molecules which indicate the presence of illness. Altered metabolism of patients offers more insight into the individual patient and potential treatments that may be effective based on the patient’s own metabolism. Stemina’s proprietary metabolomics technology is capable of identifying not only biomarkers associated with disease, but also metabolite patterns associated with toxicology and cellular response to drugs or chemicals this may be used in future studies to try to identify environmental factors associated with autism and other neurological disorders.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Private Placement
May 23, 2016

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Stemina Biomarker Discovery, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at